Navigation Links
Cerulean Pharma's Lead Candidate Selected as a "Top 10 Oncology Project to Watch"
Date:11/19/2012

CAMBRIDGE, Mass., Nov. 19, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that its lead candidate, CRLX101, was named as one of the "Top 10 Oncology Projects to Watch" by an independent panel of experts convened by Elsevier Business Intelligence and the Campbell Alliance.

The panel selected compounds using various criteria, including market size and medical need, development history, supporting science, potential for expansion beyond the initial indications and multi-level partnering opportunities.

As part of this recognition, Christopher Guiffre, senior vice president and chief business officer of Cerulean, will present the CRLX101 opportunity at Windhover's Therapeutic Area Partnerships meeting taking place on November 28 through 30, 2012, at the Westin Copley in Boston. Mr. Guiffre's presentation will occur on Thursday, November 29 at 1:40 p.m. Eastern Time.

"Cerulean's nanopharmaceuticals dynamically target tumors by entering through the large pores associated with blood vessels leading to tumors and releasing their drug inside the tumor over time," said Oliver Fetzer, Ph.D., president and chief executive officer of Cerulean. "This approach, which relies not on the patient's genetic profile but on a characteristic of blood vessels common to many tumors, allows us to evaluate CRLX101 in multiple tumor types as a monotherapy and in combination with Avastin®."

About CRLX101

CRLX101 is an investigational anti-cancer agent that is a dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha (HIF-1α). CRLX101 is designed to concentrate in tumors, prolonging drug exposure at the site of action. Significant anti-tumor activity has been observed across a wide range of cancers in animal models. CRLX101 is in Phase 2 clinical development. More information can be found at

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
2. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
5. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
8. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
9. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
10. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
11. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Men with benign prostatic hyperplasia (BPH), ... but not cancerous, have a new, breakthrough treatment ... complications than other minimally invasive treatments, such as ... according to research presented at the Society ... Meeting . Using an interventional radiology treatment known ...
(Date:3/3/2015)... -- Although lung cancer is the third most prevalent ... drugs in the market for its treatment. Further, popular ... patent expiry in 2015 and 2017 respectively. As such, ... drug manufacturers are vying to tap into. Approximately 130 ... (SCLC) and non-small cell lung cancer (NSCLC) are in ...
(Date:3/3/2015)... Chrono Therapeutics , a pioneer in ... Rock Health , the leading seed fund in digital ... transdermal drug delivery system and real-time behavioral support program ... than 500,000 Americans each year, and is responsible for ... United States . Of the 45 million smokers ...
Breaking Medicine Technology:Interventional radiology offers new treatment for enlarged prostates 2Interventional radiology offers new treatment for enlarged prostates 3Interventional radiology offers new treatment for enlarged prostates 4Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 2Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 3Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 3
... Reportlinker.com announces that a new market research ... Top Medical Devices and Imaging ... This research service discusses ... have excellent growth potential in the next ...
... , Pharma IQ has just published ... recently among 3,000,pharmaceutical distribution specialist with over 83 ... their respective,companies. The results showed that ... current level of service they received from,external partners ...
Cached Medicine Technology:Reportlinker Adds Top Medical Devices and Imaging Technologies 2011 2Pharma IQ's Pharma Distribution Survey report 2Pharma IQ's Pharma Distribution Survey report 3
(Date:3/3/2015)... Prophecy Healthcare®, Inc., the nation's ... testing, is now conducting dedicated research to expand ... of acquiring the exam rights and Intellectual Property ... the research will soon create more health care ... healthcare staffing organizations and more. , ...
(Date:3/3/2015)... 2015 Extend Nutrition, a leading nutritional snack ... of calories consumed at the next meal by an average ... are no lifestyle changes needed and no program to abide ... , The starter kit contains 60 servings of nutritional bars, ... protein, fiber, healthy fat and complex carbohydrates that helps to ...
(Date:3/3/2015)... 03, 2015 Getting to the truth of ... and well-being are at stake. So when it comes to ... move about pain-free – it’s vital to separate fact from ... resource, according to Sridhar Yalamanchili, PT, MSPT, and Director of ... A September 2014 nationwide survey by the American Physical Therapy ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Human ... that it’s offering a new master health insurance plan ... its clients with a group platform removing potential cost ... Master Health Plan has been in effect since January ... clients with much need medical cost savings. , The ...
(Date:3/3/2015)... Sponsors of Medicare Advantage (MA) plans and stand-alone ... changes to sift through as a result of CMS’s ... Feb. 20. The potential pay changes alone are tough ... type and location of the plan’s membership. But there ... before CMS issues the final notice and when 2016 ...
Breaking Medicine News(10 mins):Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 2Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 3Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 2Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 3Health News:Separating Fact from Fiction about Physical Therapy 2Health News:Separating Fact from Fiction about Physical Therapy 3Health News:HCBR Group Offers Master Healthcare Plan through Humana 2Health News:March 12 Webinar to Analyze Implications of CMS’s ’45-Day Notice’ and 2016 Call Letter for MA and Part D Plans 2
... PORTLAND, Ore. Researchers at Oregon Health & Science University,s ... women at high-risk for ovarian cancer who also want to ... which serve as the "breeding ground" for ovarian cancer, may ... would be a vast improvement over the current prevention strategy ...
... HealthDay Reporter , WEDNESDAY, April 6 (HealthDay News) ... not to mention the Grim Reaper, a new study from ... go shopping daily live longer than their less shopping-prone peers. ... women, according to the study, which was published recently in ...
... TORONTO, Ont., April 7, 2011 Virtual reality and other ... according to research from St. Michael,s Hospital. Patients ... up to five times more likely to show improvements in ... "Virtual reality gaming is a promising and potentially ...
... doctors more accountable for health care quality, more attention must ... to evaluate caregivers, says a prominent Johns Hopkins patient safety ... Health Affairs , Peter J. Pronovost, M.D., Ph.D., a ... Hopkins University School of Medicine, argues that as the desire ...
... Biology and Medicine is pleased to announce the 2011 ... $500 travel grant for undergraduate/ graduate students and/or individuals ... members of the Society to attend the Experimental Biology ... of their research work which were evaluated by a ...
... three-year follow-up study of patients in the Hepatitis ... revealed that increased mortality among patients with advanced ... was attributed to non-liver related causes and occurred ... to this excess mortality was evident to researchers, ...
Cached Medicine News:Health News:Ovarian cancer finding may be a 'win-win' for at-risk women who wish to have a family 2Health News:'Retail Therapy' Might Really Work 2Health News:'Retail Therapy' Might Really Work 3Health News:Video games effective treatment for stroke patients: study 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 3Health News:SEBM Young Investigator Awards for 2011 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 3
... Our most popular onsite test! QuickScreen multi-panel ... urine sample, and your choice of any ... multi-panels offer total flexibility for your drug ... the specimen and the built-in timer tells ...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. This ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
Medicine Products: